CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit public-private partnership led by Boston University that provides non-dilutive grant funding plus scientific, regulatory, and business support to early-stage developers of antibiotics, vaccines, diagnostics, and other products targeting drug-resistant bacteria. Since its inception, it has supported 121 R&D projects across 14 countries, with funding from BARDA, Wellcome, the Gates Foundation, and other government and philanthropic partners.
“It will pay up to $780 million for LimmaTech, a Swiss firm focused on bacterial pathogens like Staphylococcus aureus. It had raised $40m from firms like Tenmile, Repair Impact Fund, AXA Investment Managers, Novo Holdings, Adjuvant Capital and CARB-X.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.